REDWOOD CITY, Calif. -- (Business Wire)
Vantage Health, Inc. (OTCQB: VNTH) ("Vantage Health" or the "Company"),
announced today an article which was published by Adrienne LaFrance of
The Atlantic, an on-line publication and magazine, entitled “A
Breathalyzer That Can Diagnose Cancer”.
For the past two decades, Raed Dweik, a doctor who runs the pulmonary
vascular program at the Cleveland Clinic’s Respiratory Institute has
been studying the molecular patterns in the breath that can reveal
what’s happening inside the body.
Dr. Dweik cites in the article, “The Holy Grail of breath testing would
be a breathalyzer-style device that a person could carry in her
pocketbook and use anytime.”
Vantage Health, Inc. is developing such a device, the Vantage Health
Sensor, with clinical trials planned for later this year. To view the
articles please click on the following links:
http://www.theatlantic.com/health/archive/2014/05/a-breathalyzer-that-can-diagnose-cancer/362102/
https://www.yahoo.com/tech/a-breathalyzer-that-can-diagnose-cancer-85624950229.html
About Vantage Health Inc.
Vantage Health Inc. - a leading mobile health technology company - is
developing personalized and point-of-care screening using Apps based
upon chemical sensing residing within a small device attached to a
smartphone.
With its foundations in advanced nanotechnology, the company’s first
product, the Vantage Health Sensor, is the convergence of
nano-electronics, bio-informatics, and wireless technology to create the
next generation mobile health application. The first mobile App is
expected to be for lung cancer screening with additional mobile
healthcare Apps in the planning stages. The company has offices in
Redwood City, CA and New York. For more information, please visit http://www.vantagehealthinc.com
This press release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995 that
involve risks and uncertainties that could cause actual results to be
materially different from historical results or from any future results
expressed or implied by such forward-looking statements. Such
forward-looking statements include, among other things statements with
respect to our objectives and strategies to achieve those objectives, as
well as statements with respect to our beliefs, plans, expectations,
anticipations, estimates or intentions. Such forward-looking statements
may also include statements, among other things, concerning the
efficacy, safety and intended utilization of Vantage’s product
candidates, the conduct and results of future clinical trials, plans
regarding regulatory filings, future research and clinical trials and
plans regarding partnering activities. Factors that may cause actual
results to differ materially include, among others, the risk that
product candidates that appeared promising in early research and
clinical trials do not demonstrate safety and/or efficacy in
larger-scale or later clinical trials, trials may have difficulty
enrolling, Vantage may not obtain approval to market its product
candidates, or outside financing may not be available to meet capital
requirements. These forward-looking statements are based on our current
expectations. We caution that all forward-looking information is
inherently uncertain and actual results may differ materially from the
assumptions, estimates or expectations reflected or contained in the
forward-looking information, and that actual future performance will be
affected by a number of factors, including economic conditions,
technological change, regulatory change and competitive factors, many of
which are beyond our control. Therefore, future events and results may
vary significantly from what we currently foresee.
For a further list and description of the risks and uncertainties the
Company faces, please refer to the Company’s most recent Annual Report
on Form 10-K and other periodic and other filings Vantage files with the
Securities and Exchange Commission and are available at www.sec.gov.
Such forward-looking statements are current only as of the date they are
made, and Vantage assumes no obligation to update any forward-looking
statements, whether as a result of new information, future events or
otherwise.
Contacts:
Investors:
CSIR Group, LLC.
Christine Petraglia
212-386-7082
Source: Vantage Health, Inc.
© 2024 Canjex Publishing Ltd. All rights reserved.